Check out these New Clinical Trials

1. Phase I-II Multicenter, Open-Label Study of AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Aegera's antisense compound AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase I trials and merits further evaluation in this disease. This trial is designed to determine the recommended dose of AEG35156 in patients with relapse d or refractory chronic lymphocytic leukemia (CLL) and indolent B-cell lymphomas.

2. Phase Ib Study of ISF35 in Combination with Chemotherapy (FCR) in Subjects with Relapsed, Refractory and/or 17p- Chronic Lymphocytic Leukemia (CLL)
This Phase Ib open label, non-randomized, single institution clinical trial at the University of California, San Diego, Moores Cancer Center is designed to evaluate the safety and tolerability of three repeat infusions of Memgen's ISF35 followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) in subjects with refractory, resistant, and/or 17p- CLL. ISF35 has already been used in two Phase I clinical trials.

Please go to ( for contact information.

LymphomaInfo Social